Credit Suisse’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Credit Suisse’s Portfolio AVNR Stock Details AVNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,651,002	Closed	-$28M	–	4813
2014 Q4	$28M	Buy	1,651,002 +1,565,938	+1,841%	+$22M	0.02%	714
2014 Q3	$1.01M	Sell	85,064 -83,407	-50%	-$570K	﹤0.01%	3034
2014 Q2	$950K	Sell	168,471 -881,351	-84%	-$4.06M	﹤0.01%	3330
2014 Q1	$3.85M	Buy	1,049,822 +296,945	+39%	+$1.13M	﹤0.01%	1976
2013 Q4	$2.53M	Buy	752,877 +568,755	+309%	+$2.35M	﹤0.01%	2451
2013 Q3	$778K	Sell	184,122 -14,346	-7%	-$68K	﹤0.01%	3159
2013 Q2	$912K	Buy	+198,468	New	+$682K	﹤0.01%	2868

Credit Suisse's AVNR Position: Q1 2015 in Review

Credit Suisse sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 1,651,002 shares — an estimated $28M sold.

Credit Suisse first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $28M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

Credit Suisse reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
Credit Suisse sold 1,651,002 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $28M.
Credit Suisse first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
Credit Suisse's AVANIR PHARMACEUTICALS, INC CL A position peaked at $28M in Q4 2014.
0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on Credit Suisse's 13F filing for Q1 2015, filed 6 May 2015.